Kallaeva Karina KurbanMagomedovna (Voronezh State Medical University named after N.N. Burdenko)
Kotova Iuliia Alexandrovna (Doctor of Medical Sciences, Associate Professor, Head of the Department of Clinical Laboratory Diagnostics, Head. laboratory of postgenomic research,
Voronezh State Medical University named after N.N. Burdenko
)
Luschik Marina Valeryevna (Candidate of Biological Sciences, Associate Professor of the Department of Pathological Physiology,
Voronezh State Medical University named after N.N. Burdenko
)
Ostroukhova Oksana Nikolaevna (Candidate of Medical Sciences, Associate Professor of the Department of Pathological Physiology,
Voronezh State Medical University named after N.N. Burdenko
)
Makeeva Anna Vitalievna (Candidate of Biological Sciences, assoc., head. the educational part of the Department of Pathological Physiology,
Voronezh State Medical University named after N.N. Burdenko
)
Dugusheva Valeria Alexandrovna (Assistant of the Department of Clinical Laboratory Diagnostics,
Voronezh State Medical University named after N.N. Burdenko
)
Tyurkin Igor Alexandrovich (Assistant of the Department of Clinical Laboratory Diagnostics,
Director of the Company "New Medical Technologies" LLC,
Voronezh State Medical University named after N.N. Burdenko
)
| |
This literature review is devoted to the role of lipoprotein (a) in the development of diabetes mellitus. The review draws attention to the relationship between elevated Lp(a) levels and the risk of developing type 2 diabetes, as well as its negative impact on the growth of collateral vessels and the function of endothelial cells. The concentration of Lp(a) in plasma is determined by the hepatic production of apolipoliprotein (a) [apo(a)] Lp(a), and its level can be regulated using nucleic acids. Changing behavioral and clinical risk factors may contribute to reducing Lp(a)-mediated risk of cardiovascular disease. The basic principles of clinical practice for reducing Lp(a) levels await the results of clinical trials using RNA-oriented therapies. The review also examines the role of other lipoprotein-associated proteins in the development of diabetes.
Objective: to study current data on the role of lipoprotein (a) in the development of diabetes mellitus and to assess its relationship with other risk factors for cardiovascular diseases.
Methods: statistical, bibliometric, analysis.
Results: lipoprotein(a) [Lp(a)] has an inverse relationship with the risk of type 2 diabetes in the general population (approximately <7 mg/dl). Lp(a) is produced and accumulates in the liver, less is known about its clearance from plasma. No specific receptor has been described for Lp(a) removal, and the exact mechanisms have not been determined. The risk of cardiovascular complications increases as Lp(a) levels increase according to the results in patients without T2DM. Elevated Lp(a) was significantly associated with serious cardiovascular complications, especially among patients with T2DM.
Conclusions: This study confirms the link between Lp(a) levels and cardiovascular complications, especially in diabetic patients, and indicates the potential of new therapies to reduce Lp(a) levels and prevent cardiovascular complications. However, further research is needed to better understand the mechanisms of Lp(a) influence on the development of cardiovascular diseases and the effectiveness of treatment methods.
Keywords:apolipoproteins; cardiovascular complications;; lipoprotein(a) [Lp(a)]; diabetes, PCSK9.
|
|
| |
|
Read the full article …
|
Citation link:
Kallaeva K. K., Kotova I. A., Luschik M. V., Ostroukhova O. N., Makeeva A. V., Dugusheva V. A., Tyurkin I. A. CURRENT DATA ON THE ROLE OF LIPOPROTEIN (A) IN THE DEVELOPMENT OF DIABETES MELLITUS // Современная наука: актуальные проблемы теории и практики. Серия: Естественные и Технические Науки. -2024. -№01. -С. 179-185 DOI 10.37882/2223-2966.2024.01.20 |
|
|
